The principal goal of the Developmental Research Program is to fund promising early stage projects that address important translational objectives in prevention, early detection, and therapy of pancreatic carcinoma. Our principal intent for Developmental Research Program is to bring novel translational research projects to the SPORE program. Key elements that determine priority in this program are innovation, novelty, and potential for success in translational pancreatic cancer research. All Developmental Funds will be awarded by competition based on submission of a NIH-style pilot project application. There is a requirement for clear evidence that the proposed project shows potential of developing into a larger research project that will involve human intervention for pancreatic cancer (diagnostic or therapeutic). We will have available a minimum of $350,000 a year ($50,000 from the SPORE grant, $200,000 and a year in matching funds from office of the vice chancellor at the University of Nebraska Medical Center, and $100,000 a year in funds from the UNMC Eppley Cancer Center), which will be used to fund from 4-7 projects depending on the nature of the project and the budget. We will accept applications from single investigators for focused projects with budgets of up to $50,000 or larger collaborative projects involving two or more investigators with budgets of up to $100,000.Once a year, a request for proposals (RFP) is developed by the Principal Investigator and distributed to all faculty at the University of Nebraska Medical Center, Creighton University, the University of Nebraska at Omaha, the University of Nebraska at Lincoln, University of Nebraska at Kearny, collaborating faculty at other institutions, and faculty members at other Institutions who have contacted us or have been identified by the SPORE Scientific Council, Internal Advisory Board, or External Advisory Committee as potential collaborators on existing projects or developers of important new SPORE projects related to pancreatic cancer. The projects must be translational in nature, and therefore must undertake a basic research project that has the potential of developing a human intervention within the next 7 years or a basic science investigation of a clinical observation or problem.

Public Health Relevance

The principal goal of the Developmental Research Program is to fund promising early stage projects that address important translational objectives in prevention, early detection, and therapy of pancreatic carcinoma. Our principal intent for Developmental Research Program is to bring novel translational research projects to the SPORE program. Key elements that determine priority in this program are innovation, novelty, and potential for success in translational pancreatic cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA127297-06A1
Application #
8738895
Study Section
Special Emphasis Panel (ZCA1-RPRB-0 (M1))
Project Start
2008-09-05
Project End
2019-08-31
Budget Start
2014-09-23
Budget End
2015-08-31
Support Year
6
Fiscal Year
2014
Total Cost
$81,059
Indirect Cost
$27,199
Name
University of Nebraska Medical Center
Department
Type
DUNS #
168559177
City
Omaha
State
NE
Country
United States
Zip Code
68198
Pai, Priya; Rachagani, Satyanarayana; Dhawan, Punita et al. (2016) Mucins and Wnt/β-catenin signaling in gastrointestinal cancers: an unholy nexus. Carcinogenesis 37:223-32
Gunda, Venugopal; Yu, Fang; Singh, Pankaj K (2016) Validation of Metabolic Alterations in Microscale Cell Culture Lysates Using Hydrophilic Interaction Liquid Chromatography (HILIC)-Tandem Mass Spectrometry-Based Metabolomics. PLoS One 11:e0154416
Vaz, Arokia Priyanka; Deb, Shonali; Rachagani, Satyanarayana et al. (2016) Overexpression of PD2 leads to increased tumorigenicity and metastasis in pancreatic ductal adenocarcinoma. Oncotarget 7:3317-31
Hein, Ashley L; Seshacharyulu, Parthasarathy; Rachagani, Satyanarayana et al. (2016) PR55α Subunit of Protein Phosphatase 2A Supports the Tumorigenic and Metastatic Potential of Pancreatic Cancer Cells by Sustaining Hyperactive Oncogenic Signaling. Cancer Res 76:2243-53
Wang, Yan; Kumar, Sushil; Rachagani, Satyanarayana et al. (2016) Polyplex-mediated inhibition of chemokine receptor CXCR4 and chromatin-remodeling enzyme NCOA3 impedes pancreatic cancer progression and metastasis. Biomaterials 101:108-20
Veldkamp, Christopher T; Koplinski, Chad A; Jensen, Davin R et al. (2016) Production of Recombinant Chemokines and Validation of Refolding. Methods Enzymol 570:539-65
Pai, Priya; Rachagani, Satyanarayana; Lakshmanan, Imayavaramban et al. (2016) The canonical Wnt pathway regulates the metastasis-promoting mucin MUC4 in pancreatic ductal adenocarcinoma. Mol Oncol 10:224-39
Krishn, Shiv Ram; Kaur, Sukhwinder; Smith, Lynette M et al. (2016) Mucins and associated glycan signatures in colon adenoma-carcinoma sequence: Prospective pathological implication(s) for early diagnosis of colon cancer. Cancer Lett 374:304-14
Hein, A L; Post, C M; Sheinin, Y M et al. (2016) RAC1 GTPase promotes the survival of breast cancer cells in response to hyper-fractionated radiation treatment. Oncogene 35:6319-6329
Fink, Darci M; Steele, Maria M; Hollingsworth, Michael A (2016) The lymphatic system and pancreatic cancer. Cancer Lett 381:217-36

Showing the most recent 10 out of 137 publications